Literature DB >> 20101149

The Kras mutational spectra of chemically induced lung tumors in different inbred mice mimics the spectra of KRAS mutations in adenocarcinomas in smokers versus nonsmokers.

Jason M Fritz1, Lori D Dwyer-Nield, Bridgette M Russell, Alvin M Malkinson.   

Abstract

BACKGROUND: Human lung cancer patients exhibit different KRAS mutations depending on smoking status. In a mouse model of human cancer, A/J and BALB/cBy mice treated with the tobacco carcinogen, 3-methylcholanthrene (MCA), followed by butylated hydroxytoluene (BHT)-elicited chronic inflammation develop a high multiplicity of lung tumors.
METHODS: DNA was isolated from MCA-induced lung tumors in A/J and BALB/cByJ mice. Kras codon 12 sequences from these tumors were compared to those in human lung tumors from smokers and never-smokers.
RESULTS: The distribution of Kras codon 12 mutations in MCA-induced A/J lung tumors is strikingly similar to those found in adenocarcinomas from human smokers. In contrast, codon 12 mutations in BALB/cBy mice contain predominantly G --> D mutations, which is the most common mutation in never smokers.
CONCLUSIONS: A single lung carcinogen induces different tumor initiating mutations in different strains of mice. This may be useful for investigating the role of specific KRAS mutations in adenocarcinoma pathogenesis in smokers versus never smokers, identifying mechanisms that select for certain KRAS mutations and developing new drugs that specifically target cells with different KRAS mutations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20101149      PMCID: PMC3095832          DOI: 10.1097/JTO.0b013e3181c8ce04

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  19 in total

1.  The Catalogue of Somatic Mutations in Cancer (COSMIC).

Authors:  S A Forbes; G Bhamra; S Bamford; E Dawson; C Kok; J Clements; A Menzies; J W Teague; P A Futreal; M R Stratton
Journal:  Curr Protoc Hum Genet       Date:  2008-04

2.  Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.

Authors:  R Gealy; L Zhang; J M Siegfried; J D Luketich; P Keohavong
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-04       Impact factor: 4.254

Review 3.  Immune-modulating vaccines in non-small cell lung cancer.

Authors:  John Nemunaitis; Nevin Murray
Journal:  J Thorac Oncol       Date:  2006-09       Impact factor: 15.609

4.  Association of KRAS polymorphisms with risk for lung adenocarcinoma accompanied by atypical adenomatous hyperplasias.

Authors:  Takashi Kohno; Hideo Kunitoh; Kenji Suzuki; Seiichiro Yamamoto; Aya Kuchiba; Yoshihiro Matsuno; Noriko Yanagitani; Jun Yokota
Journal:  Carcinogenesis       Date:  2008-02-24       Impact factor: 4.944

5.  Age-, tissue-, and Ah genotype-dependent differences in the binding of 3-methylcholanthrene and its metabolite(s) to mouse DNA.

Authors:  L J Lu; R G Harvey; H Lee; J R Baxter; L M Anderson
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

Review 6.  Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium.

Authors:  Alexander Yu Nikitin; Ana Alcaraz; Miriam R Anver; Roderick T Bronson; Robert D Cardiff; Darlene Dixon; Armando E Fraire; Edward W Gabrielson; William T Gunning; Diana C Haines; Matthew H Kaufman; R Ilona Linnoila; Robert R Maronpot; Alan S Rabson; Robert L Reddick; Sabine Rehm; Nora Rozengurt; Hildegard M Schuller; Elena N Shmidt; William D Travis; Jerrold M Ward; Tyler Jacks
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

7.  Selective mutation of K-ras by N-ethylnitrosourea shifts from codon 12 to codon 61 during fetal mouse lung maturation.

Authors:  G Sithanandam; G Ramakrishna; B A Diwan; L M Anderson
Journal:  Oncogene       Date:  1998-07-30       Impact factor: 9.867

Review 8.  Lung cancer in never smokers--a different disease.

Authors:  Sophie Sun; Joan H Schiller; Adi F Gazdar
Journal:  Nat Rev Cancer       Date:  2007-10       Impact factor: 60.716

9.  Additional evidence that the K-ras protooncogene is a candidate for the major mouse pulmonary adenoma susceptibility (Pas-1) gene.

Authors:  L Lin; M F Festing; T R Devereux; K A Crist; S C Christiansen; Y Wang; A Yang; K Svenson; B Paigen; A M Malkinson; M You
Journal:  Exp Lung Res       Date:  1998 Jul-Aug       Impact factor: 2.459

10.  Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse.

Authors:  M You; U Candrian; R R Maronpot; G D Stoner; M W Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

View more
  6 in total

1.  Epiregulin is required for lung tumor promotion in a murine two-stage carcinogenesis model.

Authors:  Alison K Bauer; Kalpana Velmurugan; Ka-Na Xiong; Carla-Maria Alexander; Julie Xiong; Rana Brooks
Journal:  Mol Carcinog       Date:  2016-02-19       Impact factor: 4.784

Review 2.  Inflammation as a driver and vulnerability of KRAS mediated oncogenesis.

Authors:  Shunsuke Kitajima; Rohit Thummalapalli; David A Barbie
Journal:  Semin Cell Dev Biol       Date:  2016-06-11       Impact factor: 7.727

3.  Stimulation of neoplastic mouse lung cell proliferation by alveolar macrophage-derived, insulin-like growth factor-1 can be blocked by inhibiting MEK and PI3K activation.

Authors:  Jason M Fritz; Lori D Dwyer-Nield; Alvin M Malkinson
Journal:  Mol Cancer       Date:  2011-06-24       Impact factor: 27.401

4.  Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype.

Authors:  Marta Larrayoz; Ruben Pio; María J Pajares; Isabel Zudaire; Daniel Ajona; Oriol Casanovas; Luis M Montuenga; Jackeline Agorreta
Journal:  EMBO Mol Med       Date:  2014-02-05       Impact factor: 12.137

5.  Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.

Authors:  Gilles Quéré; Renaud Descourt; Gilles Robinet; Sandrine Autret; Odile Raguenes; Brigitte Fercot; Pierre Alemany; Arnaud Uguen; Claude Férec; Isabelle Quintin-Roué; Gérald Le Gac
Journal:  BMC Cancer       Date:  2016-03-11       Impact factor: 4.430

6.  Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of Kras variant oncogenicity.

Authors:  Ian P Winters; Shin-Heng Chiou; Nicole K Paulk; Christopher D McFarland; Pranav V Lalgudi; Rosanna K Ma; Leszek Lisowski; Andrew J Connolly; Dmitri A Petrov; Mark A Kay; Monte M Winslow
Journal:  Nat Commun       Date:  2017-12-12       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.